BeiGene | To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Beigene Study ID

BGB-A317-212

ClinicalTrials.gov ID

NCT05014828

China Drug Trials ID

CTR20211874

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents